Is BLT next? Novartis to pay $8.7B for AxeXis which is developing an orphan drug. https://globenewswire.com/news-rele...s-a-gene-therapy-and-Neuroscience-leader.html
TGN Tungsten has soared +700% YTD, the US is curbing its exports, and this ASX stock is targeting production in Q1CY27